MyMD and Charles River Present Positive Preclinical Results for Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
MyMD Pharmaceuticals, Inc.®, a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
Read more